Drug Trial Radar · NCT03930732
Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation
Last checked: Nov 20, 2026Latest source record: Feb 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
939
Actual
Start
Apr 15, 2019
Primary completion
Feb 8, 2023
Study completion May 2, 2023
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Apr 29, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate and severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies (ADA)
Conditions
- Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893Drug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Inhaled CorticosteroidDrug
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Inhaled Long-Acting Beta AgonistDrug
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
Inhaled Long-Acting Muscarinic AntagonistDrug
Pharmaceutical form: Inhaled Powder Route of administration: Oral inhalation
PlaceboDrug
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment PeriodTime frame: Baseline (Day 1) to Week 52
Locations
275 sites in 24 countries. Site status is shown where the registry gives one.
SEC Clinical Research, LLC-Site Number:8400030
Andalusia, Alabama
Clinical Research Center of Alabama, LLC-Site Number:8400041
Birmingham, Alabama
UAB Lung Health Center-Site Number:8400013
Birmingham, Alabama
SEC Clinical Research, LLC-Site Number:8400059
Dothan, Alabama
Pulmonary Associates of Mobile, P.C.-Site Number:8400057
Mobile, Alabama
Asthma and Allergy Associates, PC-Site Number:8400034
Colorado Springs, Colorado
Clinical Research Of West Florida Inc-Site Number:8400010
Clearwater, Florida
Finlay Medical Research-Site Number:8400014
Greenacres City, Florida
Project 4 research, Inc.-Site Number:8400023
Miami, Florida
Finlay Medical Research-Site Number:8400062
Miami, Florida
Renstar Medical Research-Site Number:8400051
Ocala, Florida
Florida Institute for Clinical Research, LLC-Site Number:8400029
Orlando, Florida
Emerald Coast Research Associates-Site Number:8400032
Panama City, Florida
Sarasota Clinical Research-Site Number:8400026
Sarasota, Florida
VitaLink research-Hamilton Mill-Site Number:8400055
Dacula, Georgia
DC Research Works-Site Number:8400016
Marietta, Georgia
North Georgia Clinical Research-Site Number:8400025
Woodstock, Georgia
Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400012
Baltimore, Maryland
Asthma Allergy & Sinus Center-Site Number:8400038
White Marsh, Maryland
Michigan Medicine (University of Michigan)-Site Number:8400050
Ann Arbor, Michigan
Mayo Clinic Lanmark Center 2-46-Site Number:8400065
Rochester, Minnesota
Midwest Chest Consultants, P.C.-Site Number:8400011
Saint Charles, Missouri
Washington University School of Medicine-Site Number:8400004
St Louis, Missouri
Sierra Clinical Research-Site Number:8400035
Las Vegas, Nevada
Va Western New York Healthcare-Site Number:8400067
Buffalo, New York
IMA Clinical Research, LLC-Site Number:8400070
New York, New York
The University of North Carolina at Chapel Hill - Division of Pulmonary and Critical Care Medicine-Site Number:8400019
Chapel Hill, North Carolina
American Health Research-Site Number:8400061
Charlotte, North Carolina
Duke Asthma, Allergy and Airway Center-Site Number:8400064
Durham, North Carolina
Accellacare-Site Number:8400052
Wilmington, North Carolina
Southeastern Research Center-Site Number:8400060
Winston-Salem, North Carolina
Midwest Pulmonary and Sleep Research Center-Site Number:8400040
Dayton, Ohio
Aventiv Research, Inc-Site Number:8400024
Dublin, Ohio
OK Clinical Research-Site Number:8400005
Edmond, Oklahoma
Velocity Clinical Research, Medford-Site Number:8400001
Medford, Oregon
Jefferson Associates in Internal Medicine-Site Number:8400037
Clairton, Pennsylvania
Temple University Hospital-Site Number:8400009
Philadelphia, Pennsylvania
Emphysema COPD Research Center, Kaufmann Medical Building-Site Number:8400033
Pittsburgh, Pennsylvania
Berks Schuylkill Respiratory Specialists, LTD-Site Number:8400063
Wyomissing, Pennsylvania
VitaLink Research-Easley-Site Number:8400022
Easley, South Carolina
Showing 40 of 275 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.